VANCOUVER, British Columbia, Feb. 19, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, announces that it has awarded the contract to manufacture the active pharmaceutical ingredient and finished product for its formulation of AP-188 (“N,N-Dimethyltryptamine or DMT”)…


Previous articlePTSF47 – Covid, Ketamine, and Human Rights
Next articleNew Texas Legislation Will Allow State to Study MDMA, Psilocybin as Potential Treatments for Depression and PTSD